The development of metabolic risk factors after the initiation of the second line anti- retroviral therapy

Journal of Clinical and Diagnostic Research

Volumn 7, Issue 2, 2013, Pages 265-268

  Mittal, Apoorva ^a   Achappa, Basavaprabhu ^a   Madi, Deepak ^a   Chowta, Mukta N ^a   Ramapuram, John T ^a   Rao, Satish ^a   Unnikrishnan, B ^a   Mahalingam, Soundarya ^b  

^a Department of General Medicine ^*

^b KASTURBA MEDICAL COLLEGE   (India)

Author keywords

ART; Dyslipidaemia; HAART; HIV; Metabolic syndrome

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR;

ADULT; ARM CIRCUMFERENCE; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LIPID BLOOD LEVEL; LIPODYSTROPHY; MALE; MEDICAL ASSESSMENT; SIDE EFFECT; TERTIARY HEALTH CARE; TREATMENT DURATION; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 84873895167     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2013/4740.2743     Document Type: Article

References (11)

1. Calza L, Manferdi R, Chiodo F. D yslipidemia associated with anti-retroviral therapy in HIV-infected patients. JAC. 2004; 53:10-14.
2. Samaras K, Wand H, Law M, Enery S, Cooper D, Carr A. Prevalence of Syndrome in HIV-Infected Patients receiving HAART Using IDF and ATP III Criteria. Diabetes Care. 2007; 30:113-19.
3. van der Valk M, Reiss P. Metabolic side effects of ART. Ned Tijdschr Geneeskd. 2008; 152:1260-64.
4. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG et al. Management of metabolic complication associated with ART for HIV-1 infection: Recommendation of an internal AIDS society USA panel. JAIDS. 2002; 31: 259-71.
5. Bernasconic E. Metabolic effects of Protease Inhibitor Therapy. AIDS. 1999; 9:254-69.
6. Erbelding EJ. Metabolic complications of Protease Inhibitors: what have we learned so far? Hopkins HIV Rep. 1999; 11:5-15.
7. Hiransuthikul N, Hiransuthikul P, Kanansook Y. Lipid profiles of Thai Adult HIV-infected patients receiving Protease Inhibitors. Southeast Asian J Trop Med Public Health. 2007; 38:69-77.
8. Rhew D, Bernal M, Aguilar D, Iloeje U, Goetz MB. Association between Protease Inhibitor Use and Increased Cardio Vascular Risk in Patients Infected with HIV: A systemic review. Clin Infect Dis. 2003; 37:959-72.
9. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ et al. Atherogenic Dyslipidemia In HIV Infected Individuals Treated with Protease Inhibitor. Circulation. 1999; 100:700-05.
10. Ena J, Benito C, Llácer P, Pasquau F, Amador C. Abnormal body fat distribution and type of ART as predictors of cardiovascular disease risk in HIV-infected patients. Med Clin(Barc). 2004; 122:721-26.
11. Estrada V, Portilla J. Dyslipidaemia related to antiretroviral therapy. AIDS Rev. 2011;13:49-56.